MB
OLMA icon

MPM BioImpact’s Olema Pharmaceuticals OLMA Stock Holding History

MPM BioImpact’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,378,762
Closed -$10.1M – 47
2025
Q2 		$10.1M Sell
2,378,762
-551,684
-19% -$2.46M 1.76% 24
2025
Q1 		$11M Buy
2,930,446
+17,896
+0.6% +$90K 1.89% 21
2024
Q4 		$17M Buy
2,912,550
+231,954
+9% +$2.32M 2.41% 16
2024
Q3 		$32M Buy
2,680,596
+25,729
+1% +$329K 4.8% 3
2024
Q2 		$28.7M Buy
2,654,867
+701,177
+36% +$7.6M 4.46% 3
2024
Q1 		$22.1M Buy
1,953,690
+96,554
+5% +$1.25M 3.56% 8
2023
Q4 		$26.1M Sell
1,857,136
-545
-0% -$7.32K 6.1% 3
2023
Q3 		$22.9M Buy
1,857,681
+1,395,181
+302% +$14.2M 6.12% 2
2023
Q2 		$4.18M Buy
+462,500
New +$2.79M 0.84% 29

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

MPM BioImpact's OLMA Position: Q3 2025 in Review

MPM BioImpact sold out of Olema Pharmaceuticals (OLMA) in Q3 2025, closing a stake of 2,378,762 shares — an estimated $10.1M sold.

MPM BioImpact first reported a position in OLMA in Q2 2023 and held it in 9 quarters. The position peaked at $32M in Q3 2024. 126 funds tracked by Wall St. Rank hold OLMA as of Q3 2025.

  • MPM BioImpact reported no remaining Olema Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • MPM BioImpact sold 2,378,762 Olema Pharmaceuticals shares in Q3 2025, an estimated $10.1M.
  • MPM BioImpact first reported a position in Olema Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • MPM BioImpact's Olema Pharmaceuticals position peaked at $32M in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2025.

Based on MPM BioImpact's 13F filing for Q3 2025, filed 14 Nov 2025.